Walder Wyss advises BioVersys AG, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics, on its Series B Financing Round. Meyerlustenberger Lachenal advised Clinical Research Ventures.
The financing round amounts to CHF 19 mio. and was subscribed by existing shareholders as well as new investors.
Clinical Research Ventures, a Singapore, Frankfurt and Boston based global life-science investor with a focus on companies entering Phase I or II clinical trials, completed its investment into BioVersys AG, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics.
The investment forms part of the recently closed series B round and will allow BioVersys to advance its two lead assets for multi-drug resistant bacterial infections through initial clinical trials. In November BioVersys announced it had successfully dosed the first patients in its phase I trial with BV100.
Walder Wyss advised BioVersys AG in connection with this transaction with a team led by Alexander Gutmans (Partner, Transaction/M&A & Venture Capital, in picture) and Robert von Rosen (Partner, Transaction/M&A & Venture Capital) and included Ayesha Curmally (Partner, Notary Services), Jessica Aeschbach Flórez (Senior Associate, Transaction/M&A) and Karina Tschon (Associate Transaction/M&A).
The MLL team was led by Marco Fusi and supported by Karin Oberlin and included Julian Kläser and Göktug Gürbüz.
Involved fees earner: Marco Fusi – MeyerLustenberger Lachenal; Göktug Gürbüz – MeyerLustenberger Lachenal; Julian Kläser – MeyerLustenberger Lachenal; Karin Oberlin – MeyerLustenberger Lachenal; Jessica Aeschbach Flórez – Walder Wyss Ltd.; Ayesha Curmally – Walder Wyss Ltd.; Alexander Gutmans – Walder Wyss Ltd.; Karina Tschon – Walder Wyss Ltd.; Robert von Rosen – Walder Wyss Ltd.;